Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Novel Immune Regulator Shows Promise as MS Therapy in Clinical Trials
Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial.
Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.
Assessment of sphingosine-1-phosphate receptor expression and associated intracellular signaling cascades in primary cells of the human central nervous system.
Liposarcoma concurrence in a multiple sclerosis patient treated with interferon-beta 1b.
Effect of met-enkephalin on chromosomal aberrations in the lymphocytes of the peripheral blood of patients with multiple sclerosis.
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome.
Rehabilitation interventions in multiple sclerosis: an overview.
Brain Hemodynamic Changes Associated with Chronic Cerebrospinal Venous Insufficiency Are Not Specific to Multiple Sclerosis and Do Not Increase Its Severity.
Recommendations for the clinical use of motor evoked potentials in multiple sclerosis.
Artielle Immunotherapeutics Announces Positive Results of Phase ! Multiple Sclerosis Trial
Targeted ablation of oligodendrocytes induces axonal pathology independent of overt demyelination.
Suppression of Murine Experimental Autoimmune Optic Neuritis by Mature Dendritic Cells Transfected with Calcitonin Gene-Related Peptide Gene.
Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with MS.
Effect of Genzyme’s LEMTRADA™ maintained in patients beyond two-year pivotal MS studies
Higher Relative Risk for Multiple Sclerosis in a Pediatric and Adolescent Diabetes Population: Analysis From DPV Data Base.
Glatiramer acetate (copaxone) modulates platelet activation and inhibits thrombin-induced calcium influx: possible role of copaxone in targeting platelets during autoimmune neuroinflammation.
Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis.
Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects.
Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.
Gilenya prescribing information
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis.
Mycoplasma pneumonia seroposivity in Iranian patients with relapsing-remitting multipl sclerosis: a randomized case-control study.
Calcitriol Modulates the CD46 Pathway in T Cells.
The International Symposium on the Multiple Sclerosis Brain

Pages